Bayer has entered into an alliance with Impli, tapping into the start-up's implantable hormone-monitoring platform, which has potential in fertility treatment and other indications.
Roivant's latest biotech company launch – Pulmovant – has made its debut with a plan to develop a respiratory drug licensed from Bayer in a deal worth up to $294 million.
